您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Vandetanib-d6
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Vandetanib-d6
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Vandetanib-d6图片
CAS NO:1174683-49-8
包装与价格:
包装价格(元)
500μg电议
1mg电议
5mg电议

产品介绍
Vandetanib-d6 (ZD6474-d6) 是氘标记的 Vandetanib。 Vandetanib (D6474) 是一种有效的口服活性 VEGFR2/KDR 酪氨酸激酶活性抑制剂 (IC50=40 nM)。 Vandetanib 对 VEGFR3/FLT4 (IC50=110 nM) 和 EGFR/HER1 (IC50=500 nM) 的酪氨酸激酶活性也有活性。
Cas No.1174683-49-8
别名ZD6474-d6
Canonical SMILESFC1=CC(Br)=CC=C1NC2=NC=NC3=CC(OCC4CCN(C([2H])([2H])[2H])CC4)=C(OC([2H])([2H])[2H])C=C32
分子式C22H18BrD6FN4O2
分子量481.4
溶解度DMSO: soluble,Methanol: soluble,THF: soluble
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Vandetanib-d6 is intended for use as an internal standard for the quantification of Vandetanib by GC- or LC-MS. Vandetanib is a broad spectrum, orally available kinase inhibitor that targets primarily tyrosine kinases, including vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR), with IC50 values in the nanomolar range.1,2 It also potently blocks non-receptor tyrosine kinases, including ABL, RET, and SRC, as well as several serine/threonine kinases.3,4 Primarily because of its effects on receptor tyrosine kinases like VEGFR and EGFR, vandetanib inhibits angiogenesis, cell growth, and metastasis and is effective against certain forms of cancer.4,5

|1. Kiselyov, A.S., Piatnitski, E., Milligan, D., et al. 1H-1,2,4-Triazol-3-yl-anilines: Novel potent inhibitors of vascular endothelial growth factor receptors 1 and 2. Chem.Biol.Drug Des. 69(5), 331-337 (2007).|2. Hennequin, L.F., Stokes, E.S.E., Thomas, A.P., et al. Novel 4-anilinoquinazolines with C-7 basic side chains: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. Journal of Medicinal Chemistry 45(6), 1300-1312 (2002).|3. Davis, M.I., Hunt, J.P., Herrgard, S., et al. Comprehensive analysis of kinase inhibitor selectivity. Nat.Biotechnol. 29(11), 1046-1051 (2011).|4. Morabito, A., Piccirillo, M.C., Falasconi, F., et al. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: Current status and future directions. Oncologist 14(4), 378-390 (2009).|5. Ton, G.N., Banaszynski, M.E., and Kolesar, J.M. Vandetanib: A novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer. Am. J. Health Syst. Pharm. 70(10), 849-855 (2013).